Comments
Loading...

Arcturus Therapeutics Analyst Ratings

ARCTNASDAQ
Logo brought to you by Benzinga Data
$8.91
-0.18-1.93%
At close: -
$8.91
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$71.00
Lowest Price Target1
$14.00
Consensus Price Target1
$47.00

Arcturus Therapeutics Analyst Ratings and Price Targets | NASDAQ:ARCT | Benzinga

Arcturus Therapeutics Holdings Inc has a consensus price target of $47 based on the ratings of 16 analysts. The high is $71 issued by William Blair on July 24, 2023. The low is $14 issued by Goldman Sachs on November 10, 2022. The 3 most-recent analyst ratings were released by Canaccord Genuity, HC Wainwright & Co., and Wells Fargo on March 10, 2025, March 7, 2025, and March 7, 2025, respectively. With an average price target of $59.33 between Canaccord Genuity, HC Wainwright & Co., and Wells Fargo, there's an implied 565.92% upside for Arcturus Therapeutics Holdings Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Nov 24
2
Dec 24
3
Jan
2
Feb
4
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Canaccord Genuity
HC Wainwright & Co.
Wells Fargo
BTIG
Leerink Partners

1calculated from analyst ratings

Analyst Ratings for Arcturus Therapeutics

Buy NowGet Alert
03/10/2025Buy Now663.19%Canaccord Genuity
Whitney Ijem42%
$74 → $68MaintainsBuyGet Alert
03/07/2025Buy Now573.4%HC Wainwright & Co.
Ed Arce56%
$63 → $60MaintainsBuyGet Alert
03/07/2025Buy NowCantor Fitzgerald
Pete Stavropoulos40%
ReiteratesOverweight → OverweightGet Alert
03/07/2025Buy Now461.17%Wells Fargo
Yanan Zhu35%
$58 → $50MaintainsOverweightGet Alert
02/18/2025Buy Now607.07%HC Wainwright & Co.
Ed Arce56%
$63 → $63ReiteratesBuy → BuyGet Alert
02/14/2025Buy Now607.07%HC Wainwright & Co.
Ed Arce56%
$63 → $63ReiteratesBuy → BuyGet Alert
01/28/2025Buy Now360.16%BTIG
Thomas Shrader40%
→ $41Initiates → BuyGet Alert
01/13/2025Buy Now607.07%HC Wainwright & Co.
Ed Arce56%
$63 → $63ReiteratesBuy → BuyGet Alert
01/07/2025Buy Now607.07%HC Wainwright & Co.
Ed Arce56%
$63 → $63MaintainsBuyGet Alert
12/17/2024Buy Now607.07%HC Wainwright & Co.
Ed Arce56%
$63 → $63ReiteratesBuy → BuyGet Alert
12/16/2024Buy NowCantor Fitzgerald
Pete Stavropoulos40%
ReiteratesOverweight → OverweightGet Alert
11/08/2024Buy Now607.07%HC Wainwright & Co.
Ed Arce56%
$63 → $63ReiteratesBuy → BuyGet Alert
10/01/2024Buy Now607.07%HC Wainwright & Co.
Ed Arce56%
$63 → $63ReiteratesBuy → BuyGet Alert
09/09/2024Buy NowCantor Fitzgerald
Josh Schimmer51%
Reiterates → OverweightGet Alert
08/12/2024Buy Now685.63%Leerink Partners
Lili Nsongo6%
→ $70Initiates → OutperformGet Alert
08/08/2024Buy Now607.07%HC Wainwright & Co.
Ed Arce56%
$60 → $63MaintainsBuyGet Alert
08/06/2024Buy NowCantor Fitzgerald
Pete Stavropoulos40%
Reiterates → OverweightGet Alert
07/02/2024Buy Now573.4%HC Wainwright & Co.
Ed Arce56%
$60 → $60ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now865.21%Canaccord Genuity
Whitney Ijem42%
$87 → $86MaintainsBuyGet Alert
03/20/2024Buy Now573.4%HC Wainwright & Co.$60 → $60ReiteratesBuy → BuyGet Alert
03/11/2024Buy Now876.43%Canaccord Genuity
Whitney Ijem42%
$81 → $87MaintainsBuyGet Alert
03/08/2024Buy Now550.95%Wells Fargo
Yanan Zhu35%
$45 → $58MaintainsOverweightGet Alert
03/08/2024Buy Now573.4%HC Wainwright & Co.
Ed Arce56%
$60 → $60ReiteratesBuy → BuyGet Alert
02/08/2024Buy Now438.72%Citigroup
Yigal Nochomovitz54%
$40 → $48MaintainsBuyGet Alert
12/13/2023Buy NowCanaccord Genuity
Whitney Ijem42%
Initiates → BuyGet Alert
11/28/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51ReiteratesBuy → BuyGet Alert
11/15/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51ReiteratesBuy → BuyGet Alert
09/27/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51ReiteratesBuy → BuyGet Alert
09/20/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51ReiteratesBuy → BuyGet Alert
09/05/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51ReiteratesBuy → BuyGet Alert
08/22/2023Buy Now506.06%Cantor Fitzgerald
Pete Stavropoulos40%
→ $54ReiteratesOverweight → OverweightGet Alert
08/15/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51ReiteratesBuy → BuyGet Alert
07/24/2023Buy Now696.86%William Blair
Myles Minter40%
→ $71Initiates → OutperformGet Alert
07/14/2023Buy NowGuggenheim
Seamus Fernandez56%
MaintainsBuyGet Alert
07/14/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51ReiteratesBuy → BuyGet Alert
07/14/2023Buy Now506.06%Cantor Fitzgerald
Pete Stavropoulos40%
→ $54ReiteratesOverweight → OverweightGet Alert
06/01/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51Reiterates → BuyGet Alert
05/11/2023Buy Now472.39%HC Wainwright & Co.
Ed Arce56%
→ $51UpgradeNeutral → BuyGet Alert
03/29/2023Buy Now304.04%Guggenheim
Seamus Fernandez56%
→ $36Reiterates → BuyGet Alert
03/29/2023Buy Now113.24%HC Wainwright & Co.
Ed Arce56%
→ $19Reiterates → NeutralGet Alert
11/10/2022Buy Now57.13%Goldman Sachs
Madhu Kumar73%
$8 → $14MaintainsSellGet Alert
11/10/2022Buy Now102.02%Baird
Joel Beatty65%
→ $18DowngradeNeutral → UnderperformGet Alert
11/03/2022Buy NowCitigroup
Yigal Nochomovitz54%
UpgradeNeutral → BuyGet Alert
11/02/2022Buy Now180.58%Barclays
Gena Wang50%
$16 → $25UpgradeUnderweight → Equal-WeightGet Alert
11/02/2022Buy Now393.83%Cantor Fitzgerald
Pete Stavropoulos40%
$39 → $44MaintainsOverweightGet Alert
08/10/2022Buy Now999.89%Wells Fargo
Yanan Zhu35%
$105 → $98MaintainsOverweightGet Alert
08/10/2022Buy Now79.57%Barclays
Gena Wang50%
$17 → $16MaintainsUnderweightGet Alert
08/10/2022Buy NowRaymond James
Steven Seedhouse59%
DowngradeMarket Perform → UnderperformGet Alert
07/19/2022Buy Now337.71%Cantor Fitzgerald
Pete Stravropoulos58%
→ $39Assumes → OverweightGet Alert
05/24/2022Buy Now-10.21%Goldman Sachs
Madhu Kumar73%
$14 → $8MaintainsSellGet Alert
05/11/2022Buy Now57.13%Goldman Sachs
Madhu Kumar73%
$16 → $14MaintainsSellGet Alert
05/11/2022Buy Now102.02%Baird
Joel Beatty65%
$21 → $18UpgradeUnderperform → NeutralGet Alert
05/10/2022Buy Now90.8%Barclays
Gena Wang50%
$21 → $17MaintainsUnderweightGet Alert
05/10/2022Buy Now113.24%HC Wainwright & Co.
Ed Arce56%
$25 → $19MaintainsNeutralGet Alert

FAQ

Q

What is the target price for Arcturus Therapeutics (ARCT) stock?

A

The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Canaccord Genuity on March 10, 2025. The analyst firm set a price target for $68.00 expecting ARCT to rise to within 12 months (a possible 663.19% upside). 19 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arcturus Therapeutics (ARCT)?

A

The latest analyst rating for Arcturus Therapeutics (NASDAQ:ARCT) was provided by Canaccord Genuity, and Arcturus Therapeutics maintained their buy rating.

Q

When was the last upgrade for Arcturus Therapeutics (ARCT)?

A

The last upgrade for Arcturus Therapeutics Holdings Inc happened on May 11, 2023 when HC Wainwright & Co. raised their price target to $51. HC Wainwright & Co. previously had a neutral for Arcturus Therapeutics Holdings Inc.

Q

When was the last downgrade for Arcturus Therapeutics (ARCT)?

A

The last downgrade for Arcturus Therapeutics Holdings Inc happened on November 10, 2022 when Baird changed their price target from N/A to $18 for Arcturus Therapeutics Holdings Inc.

Q

When is the next analyst rating going to be posted or updated for Arcturus Therapeutics (ARCT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcturus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcturus Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.

Q

Is the Analyst Rating Arcturus Therapeutics (ARCT) correct?

A

While ratings are subjective and will change, the latest Arcturus Therapeutics (ARCT) rating was a maintained with a price target of $74.00 to $68.00. The current price Arcturus Therapeutics (ARCT) is trading at is $8.91, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch